menu
    • menu
    [{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"},{"orgOrder":0,"company":"Sensorion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"FRANCE","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Azasetron","moa":"serotonin 5-HT3 antagonists","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase II\/ Phase III","graph3":"Sensorion","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sensorion \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Sensorion \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for NCGC00024563-05

    Menu

    NCGC00024563-05

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorion provides update on SENS-401 SSNHL Phase 2 AUDIBLE-S trial enrollment

                            Details : Patient recruitment rates from this trial now indicate the data will be available by mid-year 2021, which is later than previously announced.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 13, 2020

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorion gets approval to add new sites to Phase II trial of SENS-401

                            Details : Named AUDIBLE-S, the Phase II trial is being conducted to evaluate a 43.5mg and 29mg twice-daily dose of SENS-401 for four weeks in patients suffering from severe or profound SSNHL.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2020

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorion Receives Ethics Committee Approval to Include New Military Sites in SENS-401 Phase 2 study

                            Details : The new centers will recruit volunteer military personnel exposed to impulse noise during their professional activities and suffering from hearing loss.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 17, 2020

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Sensorion

                            France arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Sensorion Presents New SENS-401 Preclinical Data at ARO Midwinter Meeting 2020

                            Details : SENS-401 significantly reduces ABR wave 1 amplitude loss after chronic noise exposure in a rat model.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 30, 2020

                            Lead Product(s) : Azasetron

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth